Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis

Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis

Abstract Background Long-term antiviral treatments are associated with a significantly lower hepatocellular carcinoma (HCC) incidence in chronic hepatitis B (CHB) patients by reducing HBV DNA concentrations. However, it is still controversial whether antiviral strategies affect HCC development in an...

Full description

Bibliographic Details
Main Authors: Ze-Hong Huang, Gui-Yang Lu, Ling-Xian Qiu, Guo-Hua Zhong, Yue Huang, Xing-Mei Yao, Xiao-Hui Liu, Shou-Jie Huang, Ting Wu, Quan Yuan, Ying-Bin Wang, Ying-Ying Su, Jun Zhang, Ning-Shao Xia
Format: Article
Language:English
Published: BMC 2022-03-01
Series:BMC Cancer
Subjects:
Chronic hepatitis B
Hepatocellular carcinoma
Entecavir
Tenofovir
Cirrhosis
Online Access:https://doi.org/10.1186/s12885-022-09413-7

Internet

https://doi.org/10.1186/s12885-022-09413-7

Similar Items